Gregory Aram Daniels MD

Oncology•San Diego, CA

Clinical Professor at UCSD School of Medicine

Join to View Full Profile

200 W Arbor DrUcsd Medical CenterSan Diego, CA 92103
Phone+1 858-822-6100
Fax+1 619-543-3183

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2002 - 2005
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1999 - 2002
Keck School of Medicine of the University of Southern CaliforniaClass of 1999

Certifications & Licensure

CA State Medical License 2005 - 2025
MN State Medical License 2000 - 2006
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2012

Clinical Trials

Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma Start of enrollment: 2006 Feb 01
Completed
Phase 1
A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma Start of enrollment: 2007 Jun 01
Unknown status
Phase 2
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01
Completed
Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer Start of enrollment: 2012 Apr 01
Completed
Phase 1
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Start of enrollment: 2012 Aug 01
Terminated
Phase 4
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. Start of enrollment: 2013 Jul 01
Terminated
Phase 1, Phase 2
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2013 Oct 14
Completed
Phase 2
Phase 1A/1B Study of PSA/IL-2/GM-CSF Vaccine for Recurrent Prostate Cancer in Hormone Naive and Hormone Independent Patients Start of enrollment: 2012 Apr 01
Unknown status
Phase 1
Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors Start of enrollment: 2020 Oct 07
Recruiting
Phase 1
High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma Start of enrollment: 2019 May 23
TERMINATED
PHASE2
Roles: Principal Investigator, Contact, Sponsor-Investigator
Join now to see all

Publications & Presentations

PubMed

Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma.
Erin McGillivray, Karam Ashouri, Eftychia Chatziioannou, Jesús Antonio Ocejo Gallegos, Jabra Zarka
The British Journal of Dermatology. 2025-01-24
Racial Differences in Systemic Immune Parameters in Individuals With Lung Cancer.
Mitchell S von Itzstein, Jialiang Liu, Hong Mu-Mosley, Farjana Fattah, Jason Y Park
JTO Clinical and Research Reports. 2025-01-01
1 citations
Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab.
Helen Gogas, Shruthi Ravimohan, Antara Datta, Aparna Chhibber, Eva Muñoz Couselo
NPJ Precision Oncology. 2024-07-19

Press Mentions

Despite COVID-19 Pandemic First Patient Undergoes New Personalized ImmunotherapyDecember 10th, 2020
Deciding Between Surgery or Systemic TherapyJune 4th, 2019
UC San Diego Health First in Region to Provide Novel Therapy for MelanomaJune 5th, 2024